Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Idelalisib in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Conditions
Interventions
Idelalisib
Locations
6
Denmark
Aarhus University Hospital
Aarhus C, Denmark
Odense University Hospital
Odense, Denmark
Halmstad County Hospital
Halmstad, Sweden
Linkoping University Hospital
Linköping, Sweden
Skane University Hospital
Lund, Sweden
Karolinska University Hospital
Stockholm, Sweden
Start Date
July 7, 2017
Primary Completion Date
September 30, 2021
Completion Date
September 30, 2021
Last Updated
October 13, 2021
NCT05006716
NCT06026319
NCT07368270
NCT07255963
NCT05940272
NCT06352242
Lead Sponsor
Nordic Lymphoma Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions